Nantahala Capital Management, LLC 4

Accession 0001104659-25-123156

CIK 0001403708other

Filed

Dec 18, 7:00 PM ET

Accepted

Dec 19, 4:15 PM ET

Size

20.8 KB

Accession

0001104659-25-123156

Form 4

Period: 2025-12-17

10% Owner

Transactions

Other
Common Stock
2025-12-17$11.00/sh−148,153$1,629,683→ 0 total(indirect: See Footnote)
Other
Prefunded Warrants
2025-12-17$11.00/sh−433,962$4,773,148→ 0 total(indirect: See Footnote)
Exercise: $0.00From: 2024-02-13Exp: 2029-02-13→ Common Stock (433,962 underlying)
Other
Series A Common Stock Purchase Warrants
2025-12-17$4.71/sh−117,019$551,159→ 0 total(indirect: See Footnote)
Exercise: $8.16From: 2024-02-13Exp: 2029-02-13→ Common Stock (117,019 underlying)
Other
Series C Common Stock Purchase Warrants
2025-12-17$4.71/sh−117,019$551,159→ 0 total(indirect: See Footnote)
Exercise: $8.16From: 2029-02-13Exp: 2029-02-13→ Common Stock (117,019 underlying)
Other
Amended Series A Common Stock Purchase Warrants
2025-12-17$10.99/sh−158,531$1,742,256→ 0 total(indirect: See Footnote)
Exercise: $0.01From: 2024-09-27Exp: 2029-02-13→ Common Stock (158,531 underlying)
Other
Amended Series C Common Stock Purchase Warrants
2025-12-17$10.99/sh−250,627$2,754,391→ 0 total(indirect: See Footnote)
Exercise: $0.01From: 2024-09-27Exp: 2029-02-13→ Common Stock (250,627 underlying)

10% Owner

Transactions

Other
Common Stock
2025-12-17$11.00/sh−148,153$1,629,683→ 0 total(indirect: See Footnote)
Other
Prefunded Warrants
2025-12-17$11.00/sh−433,962$4,773,148→ 0 total(indirect: See Footnote)
Exercise: $0.00From: 2024-02-13Exp: 2029-02-13→ Common Stock (433,962 underlying)
Other
Series A Common Stock Purchase Warrants
2025-12-17$4.71/sh−117,019$551,159→ 0 total(indirect: See Footnote)
Exercise: $8.16From: 2024-02-13Exp: 2029-02-13→ Common Stock (117,019 underlying)
Other
Series C Common Stock Purchase Warrants
2025-12-17$4.71/sh−117,019$551,159→ 0 total(indirect: See Footnote)
Exercise: $8.16From: 2029-02-13Exp: 2029-02-13→ Common Stock (117,019 underlying)
Other
Amended Series A Common Stock Purchase Warrants
2025-12-17$10.99/sh−158,531$1,742,256→ 0 total(indirect: See Footnote)
Exercise: $0.01From: 2024-09-27Exp: 2029-02-13→ Common Stock (158,531 underlying)
Other
Amended Series C Common Stock Purchase Warrants
2025-12-17$10.99/sh−250,627$2,754,391→ 0 total(indirect: See Footnote)
Exercise: $0.01From: 2024-09-27Exp: 2029-02-13→ Common Stock (250,627 underlying)

10% Owner

Transactions

Other
Common Stock
2025-12-17$11.00/sh−148,153$1,629,683→ 0 total(indirect: See Footnote)
Other
Prefunded Warrants
2025-12-17$11.00/sh−433,962$4,773,148→ 0 total(indirect: See Footnote)
Exercise: $0.00From: 2024-02-13Exp: 2029-02-13→ Common Stock (433,962 underlying)
Other
Series A Common Stock Purchase Warrants
2025-12-17$4.71/sh−117,019$551,159→ 0 total(indirect: See Footnote)
Exercise: $8.16From: 2024-02-13Exp: 2029-02-13→ Common Stock (117,019 underlying)
Other
Series C Common Stock Purchase Warrants
2025-12-17$4.71/sh−117,019$551,159→ 0 total(indirect: See Footnote)
Exercise: $8.16From: 2029-02-13Exp: 2029-02-13→ Common Stock (117,019 underlying)
Other
Amended Series A Common Stock Purchase Warrants
2025-12-17$10.99/sh−158,531$1,742,256→ 0 total(indirect: See Footnote)
Exercise: $0.01From: 2024-09-27Exp: 2029-02-13→ Common Stock (158,531 underlying)
Other
Amended Series C Common Stock Purchase Warrants
2025-12-17$10.99/sh−250,627$2,754,391→ 0 total(indirect: See Footnote)
Exercise: $0.01From: 2024-09-27Exp: 2029-02-13→ Common Stock (250,627 underlying)

Footnotes (2)

[F1]These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
[F2]Nantahala Capital Management, LLC ("NCM"), an investment adviser to certain private funds and managed accounts (the "NCM Investors") that hold the Evoke Pharma, Inc. ("Issuer") securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.

Documents

1 file

Evoke Pharma Inc

CIK 0001403708

Entity typeother

IncorporatedMA